Switch to: References

Add citations

You must login to add citations.
  1. Ethical issues in nanomedicine: Tempest in a teapot?Irit Allon, Ahmi Ben-Yehudah, Raz Dekel, Jan-Helge Solbakk, Klaus-Michael Weltring & Gil Siegal - 2017 - Medicine, Health Care and Philosophy 20 (1):3-11.
    Nanomedicine offers remarkable options for new therapeutic avenues. As methods in nanomedicine advance, ethical questions conjunctly arise. Nanomedicine is an exceptional niche in several aspects as it reflects risks and uncertainties not encountered in other areas of medical research or practice. Nanomedicine partially overlaps, partially interlocks and partially exceeds other medical disciplines. Some interpreters agree that advances in nanotechnology may pose varied ethical challenges, whilst others argue that these challenges are not new and that nanotechnology basically echoes recurrent bioethical dilemmas. (...)
    Download  
     
    Export citation  
     
    Bookmark   1 citation  
  • Challenging research on human subjects: justice and uncompensated harms.Stephen Napier - 2013 - Theoretical Medicine and Bioethics 34 (1):29-51.
    Ethical challenges to certain aspects of research on human subjects are not uncommon; examples include challenges to first-in-human trials (Chapman in J Clin Res Bioethics 2(4):1–8, 2011), certain placebo controlled trials (Anderson in J Med Philos 31:65–81, 2006; Anderson and Kimmelman in Kennedy Inst Ethics J 20(1):75–98, 2010) and “sham” surgery (Macklin in N Engl J Med 341:992–996, 1999). To date, however, there are few challenges to research when the subjects are competent and the research is more than minimal risk (...)
    Download  
     
    Export citation  
     
    Bookmark   1 citation  
  • Assessing risk/benefit for trials using preclinical evidence: a proposal.Jonathan Kimmelman & Valerie Henderson - 2016 - Journal of Medical Ethics 42 (1):50-53.
    Download  
     
    Export citation  
     
    Bookmark   10 citations  
  • Reconceptualising risk–benefit analyses: the case of HIV cure research.Robert Steel - 2020 - Journal of Medical Ethics 46 (3):212-219.
    Modern antiretroviral therapies are capable of suppressing HIV in the bloodstream to undetectable levels. Nonetheless, people living with HIV must maintain lifelong adherence to ART to avoid the re-emergence of the infection. So despite the existence and efficacy of ART, there is still substantial interest in development of a cure. But HIV cure trials can be risky, their success is as of yet unlikely, and the medical gain of being cured is limited against a baseline of ART access. The medical (...)
    Download  
     
    Export citation  
     
    Bookmark   6 citations  
  • Intracranial Stem Cell-Based Transplantation: Reconsidering the Ethics of Phase 1 Clinical Trials in Light of Irreversible Interventions in the Brain.Pascale Hess - 2012 - American Journal of Bioethics Neuroscience 3 (2):3-13.
    Download  
     
    Export citation  
     
    Bookmark   12 citations  
  • The Nuremberg Code subverts human health and safety by requiring animal modeling.Ray Greek, Annalea Pippus & Lawrence A. Hansen - 2012 - BMC Medical Ethics 13 (1):1-17.
    The requirement that animals be used in research and testing in order to protect humans was formalized in the Nuremberg Code and subsequent national and international laws, codes, and declarations. We review the history of these requirements and contrast what was known via science about animal models then with what is known now. We further analyze the predictive value of animal models when used as test subjects for human response to drugs and disease. We explore the use of animals for (...)
    Download  
     
    Export citation  
     
    Bookmark   4 citations  
  • Participant selection for preventive Regenerative Medicine trials: ethical challenges of selecting individuals at risk.Sophie L. Niemansburg, Michelle G. J. L. Habets, Wouter J. A. Dhert, Johannes J. M. van Delden & Annelien L. Bredenoord - 2015 - Journal of Medical Ethics 41 (11):914-916.
    The innovative field of Regenerative Medicine (RM) is expected to extend the possibilities of prevention or early treatment in healthcare. Increasingly, clinical trials will be developed for people at risk of disease to investigate these RM interventions. These individuals at risk are characterised by their susceptibility for developing clinically manifest disease in future due to the existence of degenerative abnormalities. So far, there has been little debate about the ethical appropriateness of including such individuals at risk in clinical trials. We (...)
    Download  
     
    Export citation  
     
    Bookmark